{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:44:57Z","timestamp":1791215097814,"version":"4.1.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1645,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,3]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>\n                                 <jats:bold>Control of hepatitis C virus (HCV) infection remains a huge challenge of global medical importance. Using a variety of<\/jats:bold>\n                                 <jats:bold>\n                                    in vitro\n                                 <\/jats:bold>\n                                 <jats:bold>approaches, neutralizing antibodies (nAbs) have been identified in patients with acute and chronic hepatitis C. The exact role these nAbs play in the resolution of acute HCV infection still remains elusive. We have previously shown that purified polyclonal antibodies isolated from plasma obtained in 2003 from a chronic HCV patient (Patient H) can protect human liver chimeric mice from a subsequent challenge with the autologous HCV strain isolated from Patient H in 1977 (H77). In this study we investigated whether polyclonal antibodies isolated from Patient H in 2006 (H06), which display high cross-genotype neutralizing activity in both the HCV pseudoparticle (HCVpp) and HCV cell culture (HCVcc) systems, were also able to prevent HCV infection of different genotypes (gt) in vivo. Following passive immunization with H06-antibodies, chimeric mice were challenged with the consensus strains H77C (gt1a), ED43 (gt4a), or HK6a (gt6a). In accordance with previous results, H06-antibodies prevented infection of chimeric mice with the autologous virus. However, the outcome of a homologous challenge is highly influenced by the amount of challenge virus injected. Depending on the viral genotype used, H06-antibodies were able to protect up to 50% of chimeric mice from a heterologous challenge. Animals in which the antibody pretreatment failed displayed a clear delay in the kinetics of viral infection. Sequence analysis of the recovered viruses did not suggest antibody-induced viral escape.<\/jats:bold>\n                                 <jats:bold>\n                                    Conclusion:\n                                 <\/jats:bold>\n                                 <jats:bold>Polyclonal anti-HCV antibodies isolated from a chronic HCV patient can protect against an<\/jats:bold>\n                                 <jats:bold>\n                                    in vivo\n                                 <\/jats:bold>\n                                 <jats:bold>challenge with different HCV genotypes. However, the<\/jats:bold>\n                                 <jats:bold>\n                                    in vivo\n                                 <\/jats:bold>\n                                 <jats:bold>protective efficacy of cross-genotype neutralizing antibodies was less than predicted by cell culture experiments. (Hepatology 2011)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.24171","type":"journal-article","created":{"date-parts":[[2011,1,11]],"date-time":"2011-01-11T21:22:42Z","timestamp":1294780962000},"page":"755-762","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":134,"title":["In Vivo Evaluation of the Cross-Genotype Neutralizing Activity of Polyclonal Antibodies Against Hepatitis C Virus \u0394\u03c3"],"prefix":"10.1097","volume":"53","author":[{"given":"Philip","family":"Meuleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Bukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieven","family":"Verhoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Farhoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vanwolleghem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Desombere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey","family":"Alter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Purcell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Leroux-Roels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20250207","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1146\/annurev.immunol.25.022106.141602","article-title":"Flying under the radar: the immunobiology of hepatitis C.","volume":"25","author":"Dustin","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"R2-6-20250207","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1084\/jem.20021756","article-title":"Infectious hepatitis C virus pseudoparticles containing functional E1E2 envelope protein complexes.","volume":"197","author":"Bartosch","year":"2003","journal-title":"J Exp Med"},{"key":"R3-6-20250207","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1073\/pnas.0832180100","article-title":"Hepatitis C virus glycoproteins mediate pHdependent cell entry of pseudotyped retroviral particles.","volume":"100","author":"Hsu","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R4-6-20250207","doi-asserted-by":"crossref","first-page":"14199","DOI":"10.1073\/pnas.2335981100","article-title":"In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes.","volume":"100","author":"Bartosch","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R5-6-20250207","doi-asserted-by":"crossref","first-page":"10149","DOI":"10.1073\/pnas.0403519101","article-title":"Neutralizing antibody response during acute and chronic hepatitis C virus infection.","volume":"101","author":"Logvinoff","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R6-6-20250207","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1073\/pnas.0501275102","article-title":"Evidence for crossgenotype neutralization of hepatitis C virus pseudoparticles and enhancement of infectivity by apolipoprotein C1.","volume":"102","author":"Meunier","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R7-6-20250207","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1006\/clim.2001.5036","article-title":"Fiveyear followup of patients with primary antibody deficiencies following an outbreak of acute hepatitis C.","volume":"99","author":"Chapel","year":"2001","journal-title":"Clin Immunol"},{"key":"R8-6-20250207","doi-asserted-by":"crossref","first-page":"7705","DOI":"10.1073\/pnas.0402458101","article-title":"Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from antiHCVpositive plasma.","volume":"101","author":"Yu","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R9-6-20250207","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1073\/pnas.0607026104","article-title":"Rapid induction of virusneutralizing antibodies and viral clearance in a singlesource outbreak of hepatitis C.","volume":"104","author":"Pestka","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R10-6-20250207","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1084\/jem.20090766","article-title":"Viral entry and escape from antibodymediated neutralization influence hepatitis C virus reinfection in liver transplantation.","volume":"207","author":"FafiKremer","year":"2010","journal-title":"J Exp Med"},{"key":"R11-6-20250207","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1126\/science.1114016","article-title":"Complete replication of hepatitis C virus in cell culture.","volume":"309","author":"Lindenbach","year":"2005","journal-title":"Science"},{"key":"R12-6-20250207","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1268","article-title":"Production of infectious hepatitis C virus in tissue culture from a cloned viral genome.","volume":"11","author":"Wakita","year":"2005","journal-title":"Nat Med"},{"key":"R13-6-20250207","doi-asserted-by":"crossref","first-page":"9294","DOI":"10.1073\/pnas.0503596102","article-title":"Robust hepatitis C virus infection in vitro.","volume":"102","author":"Zhong","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R14-6-20250207","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1073\/pnas.0711044105","article-title":"Development of JFH1based cell culture systems for hepatitis C virus genotype 4a and evidence for crossgenotype neutralization.","volume":"105","author":"Scheel","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R15-6-20250207","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/hep.22673","article-title":"Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs.","volume":"49","author":"Gottwein","year":"2009","journal-title":"HEPATOLOGY"},{"key":"R16-6-20250207","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1002\/hep.22244","article-title":"Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liverchimeric mice from infection with a homologous hepatitis C virus strain.","volume":"47","author":"Vanwolleghem","year":"2008","journal-title":"HEPATOLOGY"},{"key":"R17-6-20250207","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/hep.20657","article-title":"Morphological and biochemical characterization of a human liver in a uPASCID mouse chimera.","volume":"41","author":"Meuleman","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R18-6-20250207","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0006-291X(03)01388-3","article-title":"A simple and rapid method to determine the zygosity of uPAtransgenic SCID mice.","volume":"308","author":"Meuleman","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"R19-6-20250207","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1046\/j.1537-2995.1990.30790385516.x","article-title":"The use of tri(nbutyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasmas subsequent fractionation.","volume":"30","author":"Piet","year":"1990","journal-title":"Transfusion"},{"key":"R20-6-20250207","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1086\/651579","article-title":"Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liverchimeric mouse models.","volume":"201","author":"Bukh","year":"2010","journal-title":"J Infect Dis"},{"key":"R21-6-20250207","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1128\/JVI.02667-09","article-title":"Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies.","volume":"84","author":"Gottwein","year":"2010","journal-title":"J Virol"},{"key":"R22-6-20250207","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/hep.22547","article-title":"AntiCD81 antibodies can prevent a hepatitis C virus infection in vivo.","volume":"48","author":"Meuleman","year":"2008","journal-title":"HEPATOLOGY"},{"key":"R23-6-20250207","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1586\/14760584.8.3.333","article-title":"Development of hepatitis C virus vaccines: challenges and progress.","volume":"8","author":"StollKeller","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"R24-6-20250207","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1073\/pnas.0511218103","article-title":"Cell culturegrown hepatitis C virus is infectious in vivo and can be recultured in vitro.","volume":"103","author":"Lindenbach","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R25-6-20250207","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1373\/clinchem.2008.119396","article-title":"uPASCID mouse with humanized liver as a model for in vivo metabolism of exogenous steroids: methandienone as a case study.","volume":"55","author":"Lootens","year":"2009","journal-title":"Clin Chem"},{"key":"R26-6-20250207","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/90968","article-title":"Hepatitis C virus replication in mice with chimeric human livers.","volume":"7","author":"Mercer","year":"2001","journal-title":"Nat Med"},{"issue":"Pt 6","key":"R27-6-20250207","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1099\/0022-1317-78-6-1341","article-title":"Complete nucleotide sequence of a type 4 hepatitis C virus variant, the predominant genotype in the Middle East.","volume":"78","author":"Chamberlain","year":"1997","journal-title":"J Gen Virol"},{"key":"R28-6-20250207","doi-asserted-by":"crossref","first-page":"8101","DOI":"10.1128\/JVI.00127-07","article-title":"The neutralizing activity of antihepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein.","volume":"81","author":"Helle","year":"2007","journal-title":"J Virol"},{"key":"R29-6-20250207","doi-asserted-by":"crossref","first-page":"7537","DOI":"10.1073\/pnas.0902749106","article-title":"Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad crossgenotype neutralizing activity.","volume":"106","author":"Zhang","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R30-6-20250207","doi-asserted-by":"crossref","first-page":"16269","DOI":"10.1073\/pnas.0705522104","article-title":"Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus.","volume":"104","author":"Johansson","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R31-6-20250207","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nm1698","article-title":"Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge.","volume":"14","author":"Law","year":"2008","journal-title":"Nat Med"},{"key":"R32-6-20250207","doi-asserted-by":"crossref","first-page":"12473","DOI":"10.1128\/JVI.01138-09","article-title":"Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus.","volume":"83","author":"Broering","year":"2009","journal-title":"J Virol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.24171","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201103000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T16:59:04Z","timestamp":1738947544000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201103000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.24171","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}